Definition And Concept
- Genomic imprinting is an epigenetic process where specific genes are expressed in a parent-of-origin-specific manner.
- Unlike standard Mendelian inheritance, where both maternal and paternal alleles are expressed, imprinting results in the silencing of one allele via epigenetic markers, leaving only one functional copy.
- This silencing occurs during gametogenesis and is primarily mediated by deoxyribonucleic acid (DNA) methylation.
The Imprinting Cycle
The lifecycle of an imprint involves three distinct stages:
- Erasure: Inherited parental imprints are cleared in the primordial germ cells of the developing fetus.
- Establishment: New imprints are established during gametogenesis (oogenesis or spermatogenesis) according to the sex of the individual.
- Maintenance: Imprints are maintained during DNA replication and mitosis post-fertilization to ensure tissue-specific gene expression throughout the individual’s life.
Molecular Mechanisms
- DNA Methylation: The addition of a methyl group to cytosine residues in CpG islands creates Differential Methylated Regions (DMRs), which are transcriptionally silent.
- Imprinting Control Regions (ICR): Cis-acting DNA sequences that regulate the imprinting of a gene cluster, potentially controlling several megabases of DNA.
- Histone Modification: Processes like acetylation, methylation, and phosphorylation of histone tails alter chromatin structure (euchromatin vs. heterochromatin), influencing gene accessibility to transcriptional machinery.
- Long Non-Coding RNA (lncRNA): Antisense transcripts can interfere with sense strand expression or recruit chromatin-modifying complexes to silence target genes.
Mechanisms Of Imprinting Defects
Clinical syndromes arise when the normally active allele is lost or silenced through four main mechanisms:
- Chromosomal Deletion: Physical loss of the active allele, representing the most common cause (e.g., approximately 70% of Prader-Willi and Angelman syndrome cases).
- Uniparental Disomy (UPD): Inheritance of both copies of a chromosome from one parent and none from the other.
- Imprinting Defects (Epimutations): Failure to erase or reset the imprint during gametogenesis despite having a normal DNA sequence.
- Point Mutations: Pathogenic variants within the active gene itself, such as the UBE3A mutation in Angelman syndrome.
Clinical Syndromes Of Imprinting
| Syndrome | Chromosome / Gene | Imprinting Defect | Key Clinical Features |
|---|---|---|---|
| Prader-Willi Syndrome (PWS) | 15q11-13 | Loss of paternal expression (e.g., SNRPN) | Neonatal hypotonia, childhood hyperphagia, morbid obesity, short stature, hypogonadism, mild to moderate intellectual disability. |
| Angelman Syndrome (AS) | 15q11-13 | Loss of maternal expression (e.g., UBE3A) | Severe intellectual disability, postnatal microcephaly, seizures, paroxysms of laughter, ataxia, absent speech. |
| Beckwith-Wiedemann Syndrome (BWS) | 11p15.5 | Overexpression of paternal IGF2 | Macrosomia, hemihyperplasia, macroglossia, omphalocele, high embryonal tumor risk. |
| Russell-Silver Syndrome (RSS) | 11p15.5 | Loss of paternal IGF2 | Severe intrauterine growth restriction, relative macrocephaly, clinodactyly, body asymmetry. |
| Temple Syndrome | 14q32 | Maternal UPD 14 | Early puberty, hypotonia, short stature. |
| Kagami-Ogata Syndrome | 14q32 | Paternal UPD 14 | Coat-hanger ribs, bell-shaped thorax, abdominal wall defects. |
| Pseudohypoparathyroidism Type 1a | GNAS | Defective maternal expression | Albright Hereditary Osteodystrophy phenotype with parathyroid hormone resistance. |
Clinical Management Principles
Management requires a multidisciplinary approach focused on the specific syndrome features:
- Nutritional Support: Feeding tubes are required for neonatal PWS; strict caloric restriction is mandatory in older children with PWS.
- Endocrinology: Growth hormone therapy is standard in PWS and RSS to improve height and body composition.
- Neurology: Aggressive seizure management is necessary in Angelman syndrome.
- Oncology: Serial screening for embryonal tumors (e.g., Wilms tumor, hepatoblastoma) with abdominal ultrasonography and alpha-fetoprotein is critical in BWS every three months until age 8.
- Genetic Counseling: Recurrence risk varies significantly based on the molecular mechanism. The risk is <1% for UPD or de novo deletions, but up to 50% for inherited imprinting center mutations or specific active gene mutations.